Technical Analysis for IKT - Inhibikase Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical IKT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | -2.34% | |
| Outside Day | Range Expansion | -2.34% | |
| Narrow Range Bar | Range Contraction | -4.40% | |
| NR7 | Range Contraction | -4.40% | |
| Inside Day | Range Contraction | -4.40% | |
| Fell Below 20 DMA | Bearish | -4.06% | |
| NR7 | Range Contraction | -4.06% | |
| Crossed Above 20 DMA | Bullish | -9.80% | |
| Fell Below 20 DMA | Bearish | -8.43% | |
| 50 DMA Resistance | Bearish | -12.84% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Down 3% | about 6 hours ago |
| Down 2 % | about 6 hours ago |
| Down 1% | about 6 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
Get a Trading Sidekick!
- Earnings date: ???
Inhibikase Therapeutics, Inc. Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Neurological Disorders Parkinson's Disease Stage Pharmaceutical Psychiatric Diagnosis Dementia Treatment Of Parkinson's Disease Aging Associated Diseases Pyridines Neurodegenerative Disorders Related Disorders Lewy Body Dementia Imatinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.8 |
| 52 Week Low | 5.12 |
| Average Volume | 90,574 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 6.53 |
| 20-Day Moving Average | 5.81 |
| 10-Day Moving Average | 5.80 |
| Average True Range | 0.47 |
| ADX | 13.07 |
| +DI | 22.09 |
| -DI | 19.93 |
| Chandelier Exit (Long, 3 ATRs ) | 6.01 |
| Chandelier Exit (Short, 3 ATRs ) | 6.52 |
| Upper Bollinger Band | 6.50 |
| Lower Bollinger Band | 5.12 |
| Percent B (%b) | 0.32 |
| BandWidth | 23.70 |
| MACD Line | -0.22 |
| MACD Signal Line | -0.26 |
| MACD Histogram | 0.033 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.17 | ||||
| Resistance 3 (R3) | 6.20 | 6.01 | 6.07 | ||
| Resistance 2 (R2) | 6.01 | 5.86 | 6.00 | 6.04 | |
| Resistance 1 (R1) | 5.79 | 5.76 | 5.69 | 5.76 | 6.00 |
| Pivot Point | 5.60 | 5.60 | 5.56 | 5.59 | 5.60 |
| Support 1 (S1) | 5.38 | 5.45 | 5.29 | 5.36 | 5.12 |
| Support 2 (S2) | 5.19 | 5.35 | 5.18 | 5.08 | |
| Support 3 (S3) | 4.97 | 5.19 | 5.05 | ||
| Support 4 (S4) | 4.95 |
